Search research articles
Contact Us
Filters
Showing results (81-90 of 117) with videos related to
Page
of 12
Sort By:
Cancer Biology & Therapy
|
July 11, 2022
Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma
Andrew Hsu, Kelsey E Huntington, Andre De Souza, et al.
JCO Precision Oncology
|
February 1, 2022
Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study
Julio Peguero, Davendra P S Sohal, Bert H O'Neil, et al.
Cancer Investigation
|
January 12, 2005
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial
Ramesh K Ramanathan, Jimmy J Hwang, William C Zamboni, et al.
American Journal of Clinical Oncology
|
February 8, 2013
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study
Suriya Jeyapalan, Jerrold Boxerman, John Donahue, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 16, 2010
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer
Tom Dipetrillo, Victor Pricolo, Jorge Lagares-Garcia, et al.
Cancer Investigation
|
December 8, 2004
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
Howard Safran, David Iannitti, Ramesh Ramanathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2011
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
Christopher H Crane, Gauri R Varadhachary, John S Yordy, et al.
Molecular Cancer Therapeutics
|
October 22, 2020
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer
Brittany A Borden, Yasmine Baca, Joanne Xiu, et al.
JAMA
|
March 6, 2008
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial
William F Regine, Kathryn A Winter, Ross A Abrams, et al.
Journal of Immunotherapy and Precision Oncology
|
January 16, 2025
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
Aung Naing, Amit Mahipal, Milind Javle, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 117) with videos related to
Sort By:
Page
of 12
Cancer Biology & Therapy
|
July 11, 2022
Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma
Andrew Hsu, Kelsey E Huntington, Andre De Souza, et al.
JCO Precision Oncology
|
February 1, 2022
Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study
Julio Peguero, Davendra P S Sohal, Bert H O'Neil, et al.
Cancer Investigation
|
January 12, 2005
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial
Ramesh K Ramanathan, Jimmy J Hwang, William C Zamboni, et al.
American Journal of Clinical Oncology
|
February 8, 2013
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study
Suriya Jeyapalan, Jerrold Boxerman, John Donahue, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 16, 2010
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer
Tom Dipetrillo, Victor Pricolo, Jorge Lagares-Garcia, et al.
Cancer Investigation
|
December 8, 2004
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
Howard Safran, David Iannitti, Ramesh Ramanathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2011
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
Christopher H Crane, Gauri R Varadhachary, John S Yordy, et al.
Molecular Cancer Therapeutics
|
October 22, 2020
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer
Brittany A Borden, Yasmine Baca, Joanne Xiu, et al.
JAMA
|
March 6, 2008
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial
William F Regine, Kathryn A Winter, Ross A Abrams, et al.
Journal of Immunotherapy and Precision Oncology
|
January 16, 2025
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
Aung Naing, Amit Mahipal, Milind Javle, et al.
Page
of 12